Jordy Cohen
@jordybc.bsky.social
Nephrologist, epidemiologist, methods nerd, climber, hypertension, MedEd, @ PennKidney
https://dbei.med.upenn.edu/staff/jordana-cohen-md-msce/
https://dbei.med.upenn.edu/staff/jordana-cohen-md-msce/
September 17, 2025 at 1:50 AM
Even when we say we will use MRAs earlier, we don’t! We showed this. Screening is associated with WAY more MRA use (probably in part because those who think to screen are more likely to treat based on best evidence)
pmc.ncbi.nlm.nih.gov/articles/PMC...
#nephjc
pmc.ncbi.nlm.nih.gov/articles/PMC...
#nephjc
September 17, 2025 at 1:47 AM
Even when we say we will use MRAs earlier, we don’t! We showed this. Screening is associated with WAY more MRA use (probably in part because those who think to screen are more likely to treat based on best evidence)
pmc.ncbi.nlm.nih.gov/articles/PMC...
#nephjc
pmc.ncbi.nlm.nih.gov/articles/PMC...
#nephjc
Captures similar people
From the AHA scientific statement on PREVENT:
www.ahajournals.org/doi/10.1161/...
#nephjc
From the AHA scientific statement on PREVENT:
www.ahajournals.org/doi/10.1161/...
#nephjc
September 17, 2025 at 1:37 AM
Captures similar people
From the AHA scientific statement on PREVENT:
www.ahajournals.org/doi/10.1161/...
#nephjc
From the AHA scientific statement on PREVENT:
www.ahajournals.org/doi/10.1161/...
#nephjc
September 17, 2025 at 1:31 AM
Same with the AHA/ACC guideline (well, close — anyone w/BP >140/90)!!
👇
👇
September 17, 2025 at 1:28 AM
Same with the AHA/ACC guideline (well, close — anyone w/BP >140/90)!!
👇
👇
Robust 6-month 24h ABPM responses vs. placebo when added to indapamide (-11 mmHg) and amlodipine (-8 mmHg) in folks with uncontrolled HTN (i.e., SBP 130-160 mmHg), not so much when added to olmesartan (-1.8 mmHg).
2/
2/
May 28, 2025 at 8:09 PM
Robust 6-month 24h ABPM responses vs. placebo when added to indapamide (-11 mmHg) and amlodipine (-8 mmHg) in folks with uncontrolled HTN (i.e., SBP 130-160 mmHg), not so much when added to olmesartan (-1.8 mmHg).
2/
2/
Recording another @freelyfiltered.bsky.social, excited to have a methods master in the house! I suspect we won't even have time to get to the supplement 😂
@hswapnil.medsky.social @kidneyboy.bsky.social #nephjc #freelyfiltered
@hswapnil.medsky.social @kidneyboy.bsky.social #nephjc #freelyfiltered
May 26, 2025 at 5:42 PM
Recording another @freelyfiltered.bsky.social, excited to have a methods master in the house! I suspect we won't even have time to get to the supplement 😂
@hswapnil.medsky.social @kidneyboy.bsky.social #nephjc #freelyfiltered
@hswapnil.medsky.social @kidneyboy.bsky.social #nephjc #freelyfiltered
April 23, 2025 at 11:03 PM
Talking about KT/V with KatieOverV @katiekwonmd.bsky.social was most definitely on my nephrology bucket list!
Recording @freelyfiltered.bsky.social with @kidneyboy.bsky.social @captainchloride.bsky.social 😎
Recording @freelyfiltered.bsky.social with @kidneyboy.bsky.social @captainchloride.bsky.social 😎
February 14, 2025 at 3:12 AM
Talking about KT/V with KatieOverV @katiekwonmd.bsky.social was most definitely on my nephrology bucket list!
Recording @freelyfiltered.bsky.social with @kidneyboy.bsky.social @captainchloride.bsky.social 😎
Recording @freelyfiltered.bsky.social with @kidneyboy.bsky.social @captainchloride.bsky.social 😎
2024 European Society of Cardiology Hypertension guideline writers agreed with this 👇
academic.oup.com/eurheartj/ar...
#NephJC
academic.oup.com/eurheartj/ar...
#NephJC
February 12, 2025 at 3:19 AM
2024 European Society of Cardiology Hypertension guideline writers agreed with this 👇
academic.oup.com/eurheartj/ar...
#NephJC
academic.oup.com/eurheartj/ar...
#NephJC
I may be sold with a nice mechanistic trial evaluating safety and target organ damage in these patients like in MAGMA #NephJC www.ahajournals.org/doi/10.1161/...
February 12, 2025 at 2:50 AM
I may be sold with a nice mechanistic trial evaluating safety and target organ damage in these patients like in MAGMA #NephJC www.ahajournals.org/doi/10.1161/...
We do have some thought provoking evidence of target organ damage in similar folks (i.e., even before reaching hypertension) #NephJC
www.ahajournals.org/doi/10.1161/...
www.ahajournals.org/doi/10.1161/...
February 12, 2025 at 2:38 AM
We do have some thought provoking evidence of target organ damage in similar folks (i.e., even before reaching hypertension) #NephJC
www.ahajournals.org/doi/10.1161/...
www.ahajournals.org/doi/10.1161/...
On the home screen, click the hashtag in the upper right 👇
NephSky is great (you can add it to your home screen) and you can use the search function to find others of interest. This gives you a lot of control over your feed, in lieu of algorithm-driven uncomfortableness
NephSky is great (you can add it to your home screen) and you can use the search function to find others of interest. This gives you a lot of control over your feed, in lieu of algorithm-driven uncomfortableness
November 15, 2024 at 3:59 AM
On the home screen, click the hashtag in the upper right 👇
NephSky is great (you can add it to your home screen) and you can use the search function to find others of interest. This gives you a lot of control over your feed, in lieu of algorithm-driven uncomfortableness
NephSky is great (you can add it to your home screen) and you can use the search function to find others of interest. This gives you a lot of control over your feed, in lieu of algorithm-driven uncomfortableness
@freelyfiltered.bsky.social covering HFpEF! As it should be
w/ @hswapnil.bsky.social @captainchloride.bsky.social @brendonneuen.bsky.social (honorary filtrate) @kidneyboy.bsky.social
@medpeedskidneys.bsky.social
w/ @hswapnil.bsky.social @captainchloride.bsky.social @brendonneuen.bsky.social (honorary filtrate) @kidneyboy.bsky.social
@medpeedskidneys.bsky.social
November 15, 2024 at 2:30 AM
@freelyfiltered.bsky.social covering HFpEF! As it should be
w/ @hswapnil.bsky.social @captainchloride.bsky.social @brendonneuen.bsky.social (honorary filtrate) @kidneyboy.bsky.social
@medpeedskidneys.bsky.social
w/ @hswapnil.bsky.social @captainchloride.bsky.social @brendonneuen.bsky.social (honorary filtrate) @kidneyboy.bsky.social
@medpeedskidneys.bsky.social
Standing room only at the Kidney Connection to HFpEF session at #KidneyWk!! Extremely high rates of HFpEF in our patients, but as @RupalMehtaMD points out, we have limited data & aren’t looking for this enough @senthil_selv @HeerspinkHiddo
November 22, 2024 at 9:38 AM
Standing room only at the Kidney Connection to HFpEF session at #KidneyWk!! Extremely high rates of HFpEF in our patients, but as @RupalMehtaMD points out, we have limited data & aren’t looking for this enough @senthil_selv @HeerspinkHiddo
Amazing job @PharmDerington presenting our VA data showing surprisingly high use of beta-blockers as first-line antihypertensive therapy despite the absence of compelling indications @adambress #Hypertension24
November 22, 2024 at 9:38 AM
Amazing job @PharmDerington presenting our VA data showing surprisingly high use of beta-blockers as first-line antihypertensive therapy despite the absence of compelling indications @adambress #Hypertension24
Proud mentor 📣 at #Hypertension24!
@RushelleByfield nailed her oral abstract describing how ambulatory BP variability was NOT associated with adverse kidney & CV outcomes after robust adjustment in a large US cohort of patients with CKD @CRICStudy followed for >9 years
@RushelleByfield nailed her oral abstract describing how ambulatory BP variability was NOT associated with adverse kidney & CV outcomes after robust adjustment in a large US cohort of patients with CKD @CRICStudy followed for >9 years
November 22, 2024 at 9:38 AM
Proud mentor 📣 at #Hypertension24!
@RushelleByfield nailed her oral abstract describing how ambulatory BP variability was NOT associated with adverse kidney & CV outcomes after robust adjustment in a large US cohort of patients with CKD @CRICStudy followed for >9 years
@RushelleByfield nailed her oral abstract describing how ambulatory BP variability was NOT associated with adverse kidney & CV outcomes after robust adjustment in a large US cohort of patients with CKD @CRICStudy followed for >9 years
Our patients die of cardiovascular disease, not kidney disease. Much of this is due to hypertension #NKFClinicals
November 22, 2024 at 9:44 AM
Our patients die of cardiovascular disease, not kidney disease. Much of this is due to hypertension #NKFClinicals
Best talk of #NKFClinicals 👌 @hswapnil
November 22, 2024 at 9:38 AM
Best talk of #NKFClinicals 👌 @hswapnil
Excellent @ConsumerReports article highlighting the need to accurately measure BP & advising home BP measurement to overcome limitations of office BP. Points to http://www.validatebp.org as a great resource for accurate devices ...
November 22, 2024 at 9:44 AM
Excellent @ConsumerReports article highlighting the need to accurately measure BP & advising home BP measurement to overcome limitations of office BP. Points to http://www.validatebp.org as a great resource for accurate devices ...
Starting off #AHA23 as a panelist in an exciting session on Critical Care Cardiology Meets Nephrology. Learning more nuances of renal physiology at a cardiology conference from @RangaswJ 🤩🥰
November 22, 2024 at 9:55 AM
Starting off #AHA23 as a panelist in an exciting session on Critical Care Cardiology Meets Nephrology. Learning more nuances of renal physiology at a cardiology conference from @RangaswJ 🤩🥰
Late breaking trials #Hypertension23 — lorundrostat, the second & more selective aldosterone synthase inhibitor. Early phase trial results are very promising (simultaneously published in JAMA) — excited to be entering a new era in antihypertensive...
November 22, 2024 at 9:55 AM
Late breaking trials #Hypertension23 — lorundrostat, the second & more selective aldosterone synthase inhibitor. Early phase trial results are very promising (simultaneously published in JAMA) — excited to be entering a new era in antihypertensive...